NO974618L - Farmasöytiske preparater for intranasal administrasjon - Google Patents

Farmasöytiske preparater for intranasal administrasjon

Info

Publication number
NO974618L
NO974618L NO974618A NO974618A NO974618L NO 974618 L NO974618 L NO 974618L NO 974618 A NO974618 A NO 974618A NO 974618 A NO974618 A NO 974618A NO 974618 L NO974618 L NO 974618L
Authority
NO
Norway
Prior art keywords
intranasal administration
pharmaceutical preparations
mixture
powder
composition comprises
Prior art date
Application number
NO974618A
Other languages
English (en)
Other versions
NO974618D0 (no
Inventor
Mitsuko Takenaga
Hiroshi Muramatsu
Tetsuji Ehata
Yasuo Kosaka
Muramatsu Hiroshi
Original Assignee
Fuji Yakuhin Kogyo Kk
Tetsuji Ehata
Igarashi Toshisato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Yakuhin Kogyo Kk, Tetsuji Ehata, Igarashi Toshisato filed Critical Fuji Yakuhin Kogyo Kk
Publication of NO974618D0 publication Critical patent/NO974618D0/no
Publication of NO974618L publication Critical patent/NO974618L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det tillveiebringes et farmasøytisk preparat for intranasal administrering og med bedre absorpsjonsevne og mindre irritasjonseffekter. Det farmasøytiske preparat omfatter en blanding av et pulver av en adsorberende harpiks og et biologisk aktivt peptid med medikamenteffekt, under den betingelse at de er tørre før eller etter blandingen.
NO974618A 1996-10-07 1997-10-06 Farmasöytiske preparater for intranasal administrasjon NO974618L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8282866A JP3020141B2 (ja) 1996-10-07 1996-10-07 経鼻投与用製剤

Publications (2)

Publication Number Publication Date
NO974618D0 NO974618D0 (no) 1997-10-06
NO974618L true NO974618L (no) 1998-04-08

Family

ID=17658107

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974618A NO974618L (no) 1996-10-07 1997-10-06 Farmasöytiske preparater for intranasal administrasjon

Country Status (16)

Country Link
US (1) US5948749A (no)
JP (1) JP3020141B2 (no)
KR (1) KR19980032364A (no)
CN (1) CN1180569A (no)
AU (1) AU3992697A (no)
CA (1) CA2217409A1 (no)
DE (1) DE19740733A1 (no)
DK (1) DK114797A (no)
ES (1) ES2126536B1 (no)
FI (1) FI973244L (no)
FR (1) FR2754453A1 (no)
GB (1) GB2322077A (no)
GR (1) GR970100333A (no)
IT (1) IT1295047B1 (no)
NO (1) NO974618L (no)
SE (1) SE9703133L (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
CA2341732C (en) 1998-08-26 2008-08-19 Teijin Limited Powder composition for nasal administration
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
CA2376763C (en) * 1999-06-30 2009-12-22 Takeda Chemical Industries, Ltd. Process for preparing lh-rh derivatives
USD463546S1 (en) 1999-10-14 2002-09-24 Becton Dickinson And Company Drug container holder
US6382204B1 (en) 1999-10-14 2002-05-07 Becton Dickinson And Company Drug delivery system including holder and drug container
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
US7812120B2 (en) 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
US20080033038A1 (en) * 2006-07-07 2008-02-07 Shytle R D Compositions of polyphenols and methods of use
ES2652415T3 (es) * 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
KR101736502B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Ｇｌｐ-1에 의한 유해 효과의 예방 방법
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US8827946B2 (en) * 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
CN103638527A (zh) * 2013-12-05 2014-03-19 浙江大学 促红细胞生成素载药纳米粒及其应用
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
CN106362158A (zh) * 2015-07-25 2017-02-01 于杰 增效药物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB792544A (en) * 1956-05-07 1958-03-26 American Home Prod Therapeutic composition
JPS4917563B1 (no) * 1970-12-28 1974-05-01
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
JPS62223131A (ja) * 1986-03-26 1987-10-01 Nitto Electric Ind Co Ltd 持続性鼻疾患治療剤
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
US5342922A (en) * 1989-03-08 1994-08-30 Washington University Inhibitors of retroviral protease
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
GB9203769D0 (en) * 1992-02-21 1992-04-08 Sandoz Ltd Improvements in or relating to organic compounds
WO1993025193A1 (fr) * 1992-06-12 1993-12-23 Teijin Limited Preparation pharmaceutique destinee a etre administree par les voies respiratoires
AU678389B2 (en) * 1992-09-10 1997-05-29 Teijin Limited 4-hydroxy-2-cyclopentenone derivative and carcinostatic and osteogenesis promoter containing the same
CA2114830C (en) * 1993-02-05 2000-06-06 Masayasu Tabe Lactone compound and process of production thereof
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤

Also Published As

Publication number Publication date
ITMI972144A1 (it) 1999-03-22
DE19740733A1 (de) 1998-04-09
NO974618D0 (no) 1997-10-06
AU3992697A (en) 1998-04-09
US5948749A (en) 1999-09-07
FI973244A7 (fi) 1998-04-08
IT1295047B1 (it) 1999-04-27
FR2754453A1 (fr) 1998-04-17
GR970100333A (el) 1998-06-30
JP3020141B2 (ja) 2000-03-15
SE9703133D0 (sv) 1997-08-29
FI973244A0 (fi) 1997-08-06
KR19980032364A (ko) 1998-07-25
CA2217409A1 (en) 1998-04-07
DK114797A (da) 1998-04-08
GB2322077A (en) 1998-08-19
FI973244L (fi) 1998-04-08
JPH10114645A (ja) 1998-05-06
ES2126536A1 (es) 1999-03-16
ES2126536B1 (es) 1999-10-01
CN1180569A (zh) 1998-05-06
SE9703133L (sv) 1998-04-08
GB9718690D0 (en) 1997-11-12

Similar Documents

Publication Publication Date Title
SE9703133D0 (sv) Pharmaceutical preparations for intranasal administration
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
IL116674A (en) Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
AU1534699A (en) Osmotic dosage form comprising first and second coats
FI943563L (fi) Uusia biologisesti aktiivisia polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus
AU5806998A (en) Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
FI953898L (fi) Glysiiniamidijohdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä lääkeaineita
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
DE69901487D1 (de) Eine didemnin verbindung enthaltende pharmazeutische formulierung
FR2577557B1 (fr) Peptides et derives peptidiques, leur preparation, leur utilisation en therapeutique et compositions pharmaceutiques les contenant
EP0177342A3 (en) Oral formulation of therapeutic proteins
CA2087543A1 (en) Heterocyclic compounds
IL105942A0 (en) Biologically active eburnamenine derivatives,their preparation and pharmaceutical compositions containing them
HUP9903353A3 (en) 7alpha-(methyl-amino-pentyl)-estratrienes, pharmaceutical preparations which contain said 7alpha-(5-methylaminopentyl) -estratrienes and use thereof for production of drugs
HUP9904210A3 (en) Analogues of camptothecin,their application as medicine and pharmaceutical compositions containing them
RU94040150A (ru) Стабильная лиофилизированная композиция тиотепа, способ ее получения
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
WO1991003226A3 (en) Pharmaceutical compositions containing aromatic polymers and therapeutic methods using the same
GEP20022751B (en) Aqueous Pharmaceutical Composition Comprising an Active Ingredient Which Is Highly Insoluble in Water
GEP20022735B (en) Pharmaceutical Compositions Containing Lamivudine and Zidovudine
KR900701300A (ko) 생물학적 활성 펩티드 및 특정음이온을 갖는 조성물 및 이것을 사용하는 방법
EP0409893A4 (en) Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
NO305792B1 (no) Substituerte benzensulfonylureaer, deres anvendelse for fremstilling av farmas°ytiske preparater og medikamenter inneholdende disse